中国P站

Gut microbiome; Dysbiosis; Carcinogenesis; Microbial diversity; Inflammation; Colorectal cancer; Host-microbe interaction; Immune modulation; Short-chain fatty acids; Probiotics; Metagenomics; Tumor microenvironment; Microbiota-derived metabolites; Cancer prevention; Microbial therapy

Introduction

In recent years, the human gut microbiome has emerged as a central player in maintaining health and preventing disease. Composed of trillions of microorganisms—including bacteria, archaea, viruses, and fungi—the gut microbiome plays vital roles in digestion, immunity, and metabolic homeostasis. A growing body of evidence has linked alterations in the composition and function of the gut microbiota, known as dysbiosis, to the development of several chronic diseases, including cancer [1-5]. Among the most compelling associations is the link between gut dysbiosis and carcinogenesis, particularly in cancers of the gastrointestinal tract such as colorectal cancer (CRC), but also extending to extraintestinal malignancies through systemic inflammatory and metabolic pathways. This evolving field highlights how microbial imbalances can contribute to oncogenesis through mechanisms such as chronic inflammation, genotoxin production, immune evasion, and disruption of epithelial barriers. Understanding these complex interactions opens new avenues for cancer prevention, early detection, and therapeutic intervention via microbiome modulation [6-10].

Discussion

The gut microbiome influences carcinogenesis through a variety of direct and indirect mechanisms. In a balanced state, beneficial commensal microbes help maintain intestinal integrity, regulate immune responses, and produce anti-inflammatory metabolites such as short-chain fatty acids (SCFAs)—notably butyrate, acetate, and propionate. These compounds inhibit histone deacetylases (HDACs), modulate immune cell function, and promote apoptosis in abnormal cells, offering a protective effect against tumor development.

However, dysbiosis, characterized by reduced microbial diversity and a shift in the abundance of specific bacterial taxa, can disrupt this protective balance. Certain pathobionts, such as Fusobacterium nucleatum, Escherichia coli (producing colibactin), and Bacteroides fragilis (producing B. fragilis toxin), have been implicated in colorectal tumorigenesis. These bacteria can adhere to epithelial cells, damage DNA, induce reactive oxygen species (ROS), and promote chronic inflammation—an established driver of cancer initiation and progression.

The host immune system plays a central role in mediating the interaction between microbiota and tumor development. Dysbiosis can impair mucosal immune responses, leading to increased permeability of the gut barrier and the translocation of microbial components such as lipopolysaccharides (LPS) into systemic circulation. This can trigger systemic inflammation and activate pathways like NF-κB and STAT3, which contribute to tumorigenesis by promoting cell proliferation, angiogenesis, and immune evasion.

Emerging research also suggests that the gut microbiome affects cancer treatment outcomes, particularly in immunotherapy. The presence of certain microbial species—such as Akkermansia muciniphila and Bifidobacterium longum—has been associated with improved responses to immune checkpoint inhibitors. Conversely, dysbiosis can hinder therapeutic efficacy and increase toxicity, emphasizing the importance of microbial balance in both cancer risk and management.

Metagenomic and metabolomic technologies have significantly advanced our ability to characterize the gut microbiome and its functions. These tools enable researchers to identify microbial signatures associated with increased cancer risk and to develop non-invasive diagnostic biomarkers based on stool or blood samples. Microbiota-derived metabolites, including secondary bile acids and tryptophan catabolites, are being investigated as potential indicators of early tumorigenic changes.

Therapeutic modulation of the microbiome represents a promising strategy in cancer prevention and treatment. Probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation (FMT) are under study as methods to restore microbial homeostasis and suppress carcinogenic pathways. For instance, high-fiber diets rich in plant-based foods are known to support beneficial microbial populations and reduce inflammation, while Western-style diets high in fat and low in fiber have been linked with dysbiosis and increased CRC risk.

Despite these advances, the field faces several challenges. Causality remains difficult to establish, as many associations between microbiota and cancer are correlative. Interindividual variability in microbiome composition, influenced by genetics, environment, and lifestyle, complicates the development of standardized preventive strategies. Ethical considerations surrounding microbiome manipulation, especially in vulnerable populations, also require careful attention.

To move forward, interdisciplinary collaborations between microbiologists, oncologists, nutritionists, and data scientists are essential. Longitudinal studies and clinical trials will help clarify the temporal relationships between dysbiosis and carcinogenesis, while mechanistic research will uncover actionable targets for intervention.

Conclusion

The gut microbiome has emerged as a pivotal factor in the intricate web of cancer biology, particularly in relation to carcinogenesis driven by chronic inflammation, genotoxic effects, and immune dysregulation. Dysbiosis, or microbial imbalance, plays a critical role in this process, increasing cancer susceptibility and potentially influencing treatment responses. By exploring the link between gut microbes and cancer, researchers and clinicians are opening new frontiers in preventive oncology—where maintaining or restoring microbial balance could significantly reduce cancer risk. While many questions remain, ongoing advances in microbiome science hold great promise for personalized prevention strategies, biomarker development, and microbiota-targeted therapies. In the coming years, the gut microbiome is poised to become not just a passive player, but a central target in the global effort to prevent and manage cancer more effectively.

References

1. Bik EM, Long CD, Armitage GC, Loomer P, Emerson J, et al. (2010). ISME J 4: 962-974.

   , ,

2. Heller D, Helmerhorst EJ, Gower AC, Siqueira WL, Paster BJ, et al. (2016). Appl Environ Microbiol 82: 1881-1888.

   , ,

3. Stoodley LH, Costerton JW, Stoodley P (2004). Nat Rev Microbiol 2: 95-108.

   , ,

4. Marsh PD (2006). BMC Oral Health 6: S14.

   , ,

5. Ferre PB, Alcaraz LD, Rubio RC, Romero H, Soro AS, et al. (2012). ISME J 6: 46-56.

   , ,

6. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, et al. (2011). Proc Natl Acad Sci USA 108: 4592-4598.

   , ,

7. Jr RJP, Shah N, Valm A, Inui T, Cisar JO, et al. (2017). Appl Environ Microbiol 83: e00407-e00417.

   , ,

8. Niemczewski B (2007). Ultrason Sonochem 14: 13-18.

   , ,

9. Niemczewski B (2009). Ultrason Sonochem 16: 402-7.

   , ,

10. Sluis LVD, Versluis M, Wu M, Wesselink P (2007). Int Endod J 40: 415-426.

    , ,